𝔖 Bobbio Scriptorium
✦   LIBER   ✦

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

✍ Scribed by W. Jonat; A. Howell; C.P. Blomqvist; W. Eiermann; G. Winblad; C.J. Tyrrell; L. Mauriac; H. Roche; S. Lundgren; R. Hellmund; M. Azab

Book ID
113404511
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
435 KB
Volume
4
Category
Article
ISSN
0960-9776

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase III trial comparing anastrozole
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
✍ Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n Å 128); anastrozole, 10 mg (n Å 130); or

Anastrozole versus megestrol acetate in
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials
✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace